Optimi Health Signs Psilocybin Supply Agreement With Halucenex Life Sciences Inc.

Halucenex to receive recently harvested first batch of psilocybe cubensis

 

VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human experiences, is pleased to announce that it has entered into a supply agreement with Halucenex Life Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is based in Windsor, Nova Scotia and is a life sciences company focused on researching novel psychedelic compounds, developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the medical benefits of psychedelic medicine.

Additionally, Optimi wishes to confirm that the supply agreement pertains to the entirety of the Company’s recently harvested first batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be supplied to Halucenex in the form of whole, dried mushroom fruiting bodies.

“This first supply agreement, coming so soon after our first complete cultivation cycle, is a powerful affirmation of our decision to pursue the development of natural, GMP psilocybin,” said Bill Ciprick, CEO of Optimi. “From this initial proof-of-concept batch, our cultivation team will continue to scale our operations to meet the demands of the sector, domestically and internationally with licensed entities and for individual patients within Canada according to the terms of the Special Access Program.”

Halucenex CEO, Bill Fleming, says the agreement with Optimi is one both companies will benefit from.

“We’re very excited to be moving forward on this supply agreement with the team at Optimi Health,” said Fleming. “Among our top priorities in the development of a psychedelic-assisted psychotherapeutic model for conditions such as anxiety and post-traumatic stress disorder has been to secure a safe, consistent supply of GMP psilocybin.”

Authorized parties interested in purchasing Optimi psilocybin and functional mushroom products should send an email to sales@optimihealth.ca where a member of the sales team will respond within 24 hours.

 

ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

Optimi Health Inc. is a homegrown, Canadian success story producing and supplying natural, EU-GMP grade psilocybin and functional mushrooms that focus on the health and wellness markets. Built with the purpose to produce scalable, natural mushroom formulations for transformational human experiences, the Company’s goal is to be the number one trusted, compassionate supplier of safe, natural GMP grade psilocybin across the world. With a vertically integrated approach, Optimi intends to cultivate, extract, process and distribute high quality functional and psychedelic mushroom products at its two facilities comprising a total of 20,000 square feet in Princeton, British Columbia.

To fully investigate the science of mushrooms, the Company has received a research exemption under Health Canada Food and Drug Regulations (FDR) for the use of psilocybin and psilocin for scientific purposes via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license under Canada’s Narcotic Control Regulations governing possession, distribution, sale, laboratory analysis of and research and development of psilocybin and psilocin formulations. Optimi is committed to expert cultivation and quality production subject to and in accordance with the terms of all applicable laws and governing regulations to ensure safe, superior Canadian fungi production.

Optimi was recently granted an amendment to its Dealer’s Licence by Health Canada, allowing the Company to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.

 

ABOUT HALUCENEX

Halucenex operates a 6000 sq ft medical facility in Windsor, Nova Scotia with six treatment rooms and a secure laboratory dedicated to performing psychedelic-assisted psychotherapy and clinical research. Halucenex intends to maintain control over all aspects of the product development process – mycological research, extraction technology, and synthetic formulation as well as drug delivery technologies, psychedelic-assisted psychotherapy and regulatory affairs.

Clinically, Halucenex is focused on researching psilocybin, psilocybin-derivatives, and other psychedelic medicine for the purposes of treating clients suffering from PTSD and anxiety using its comprehensive psilocybin-assisted psychotherapy treatment model. Halucenex is committed to advancing the science around the use of psilocybin in psychedelic-assisted psychotherapy by:

For more information or to request an interview, please contact:

Michael Kydd
Media & Stakeholder Relations Advisor
Email: michael@kyddergroup.com
Phone: +1 (902) 880 6121

 

ABOUT OPTIMI

(CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FOR INTERVIEW REQUESTS OR FURTHER INFORMATION PLEASE CONTACT:

Investor Relations
Email: investors@optimihealth.ca
Phone: +1 (902) 880 6121
Web: www.optimihealth.ca

FORWARD‐LOOKING STATEMENTS

Products do not contain psilocybin

Search
Get news & updates directly to your inbox.
Interested In Optimi? Let's Talk.